TY - JOUR
T1 - Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative
AU - Toledo, Jon B.
AU - Toledo, Estefanía
AU - Weiner, Michael W.
AU - Jack, Clifford R.
AU - Jagust, William
AU - Lee, Virginia M.Y.
AU - Shaw, Leslie M.
AU - Trojanowski, John Q.
N1 - Funding Information:
The authors thank their ADNI colleagues for their contributions to the work summarized here, which has been supported mainly by the ADNI U01 AG024904 . ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering , and the Foundation for the National Institutes of Health , and through generous contributions from the following companies and organizations: Pfizer Inc., Wyeth Research, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co. Inc., AstraZeneca AB, Novartis Pharmaceuticals Corporation, the Alzheimer’s Association, Eisai Global Clinical Development, Elan Corporation plc, Forest Laboratories, and the Institute for the Study of Aging, with participation from the U.S. Food and Drug Administration. Other support has come from AG10124 and the Marian S. Ware Alzheimer Program. V.M.Y.L. is the John H. Ware 3rd Professor for Alzheimer’s Disease Research, and J.Q.T. is the William Maul Measey-Truman G. Schnabel, Jr., MD, Professor of Geriatric Medicine and Gerontology. The authors thank the ADNI Biomarker Core for the analyses. They also thank Donald Baldwin and the Molecular Diagnosis Genotyping Facility at the University of Pennsylvania Medical Center for provision of the APOE ϵ genotyping data. J.B.T.’s work was supported by a grant from the Alfonso Martín Escudero Foundation .
PY - 2012/11
Y1 - 2012/11
N2 - Background: There is epidemiological evidence that cardiovascular risk factors (CVRF) also are risk factors for Alzheimer's disease, but there is limited information on this from neuropathological studies, and even less from in vivo studies. Therefore, we examined the relationship between CVRF and amyloid-β (Aβ) brain burden measured by Pittsburgh Compound B-positron emission tomography (PiB-PET) studies in the Alzheimer's Disease Neuroimaging Initiative. Methods: Ninety-nine subjects from the Alzheimer's Disease Neuroimaging Initiative cohort who had a PiB-PET study measure, apolipoprotein E genotyping data, and information available on CVRF (body mass index [BMI], systolic blood pressure, diastolic blood pressure [DBP], and cholesterol and fasting glucose test results) were included. Eighty-one subjects also had plasma cortisol, C-reactive protein, and superoxide dismutase 1 measurements. Stepwise regression models were used to assess the relation between the CVRF and the composite PiB-PET score. Results: The first model included the following as baseline variables: age, clinical diagnosis, number of apolipoprotein ε4 alleles, BMI (P =.023), and DBP (P =.012). BMI showed an inverse relation with PiB-PET score, and DBP had a positive relation with PiB-PET score. In the second adjusted model, cortisol plasma levels were also associated with PiB-PET score (P =.004). Systolic blood pressure, cholesterol, or impaired fasting glucose were not found to be associated with PiB-PET values. Conclusion: In this cross-sectional study, we found an association between Aβ brain burden measured in vivo and DBP and cortisol, indicating a possible link between these CVRF and Aβ burden measured by PiB-PET. These findings highlight the utility of biomarkers to explore potential pathways linking diverse Alzheimer's disease risk factors.
AB - Background: There is epidemiological evidence that cardiovascular risk factors (CVRF) also are risk factors for Alzheimer's disease, but there is limited information on this from neuropathological studies, and even less from in vivo studies. Therefore, we examined the relationship between CVRF and amyloid-β (Aβ) brain burden measured by Pittsburgh Compound B-positron emission tomography (PiB-PET) studies in the Alzheimer's Disease Neuroimaging Initiative. Methods: Ninety-nine subjects from the Alzheimer's Disease Neuroimaging Initiative cohort who had a PiB-PET study measure, apolipoprotein E genotyping data, and information available on CVRF (body mass index [BMI], systolic blood pressure, diastolic blood pressure [DBP], and cholesterol and fasting glucose test results) were included. Eighty-one subjects also had plasma cortisol, C-reactive protein, and superoxide dismutase 1 measurements. Stepwise regression models were used to assess the relation between the CVRF and the composite PiB-PET score. Results: The first model included the following as baseline variables: age, clinical diagnosis, number of apolipoprotein ε4 alleles, BMI (P =.023), and DBP (P =.012). BMI showed an inverse relation with PiB-PET score, and DBP had a positive relation with PiB-PET score. In the second adjusted model, cortisol plasma levels were also associated with PiB-PET score (P =.004). Systolic blood pressure, cholesterol, or impaired fasting glucose were not found to be associated with PiB-PET values. Conclusion: In this cross-sectional study, we found an association between Aβ brain burden measured in vivo and DBP and cortisol, indicating a possible link between these CVRF and Aβ burden measured by PiB-PET. These findings highlight the utility of biomarkers to explore potential pathways linking diverse Alzheimer's disease risk factors.
KW - Alzheimer disease
KW - Amyloid-β
KW - Blood pressure
KW - Body mass index
KW - Cortisol
KW - PiB
KW - Vascular risk factors
UR - http://www.scopus.com/inward/record.url?scp=84867865831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867865831&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2011.08.008
DO - 10.1016/j.jalz.2011.08.008
M3 - Article
C2 - 23102118
AN - SCOPUS:84867865831
SN - 1552-5260
VL - 8
SP - 483
EP - 489
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 6
ER -